Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: NTTG who wrote (11382)	6/27/2012 2:28:25 PM
From: Mammon	3 Recommendations Read Replies (2) \| Respond to of 13111

you are not sure that pv10 would do better than a comparator arm of DTIC. Reeeeeally. This from the national cancer institute website. from the website: "Chemotherapy The objective response rate to DTIC and the nitrosoureas, carmustine (BCNU) and lomustine, is approximately 10% to 20%.[ 2, 31- 33] Responses are usually short-lived, ranging from 3 to 6 months, though long-term remissions can occur in a limited number of patients who attain a complete response.[ 31, 33] A randomized trial of DTIC versus temozolomide showed an OS of 6.4 months versus 7.7 months, respectively (HR = 1.18; 95% CI, 0.92–1.52). These data suggested similarity to DTIC; however, no benefit in survival has been demonstrated for either DTIC or temozolomide; therefore, temozolomide did not receive approval from the FDA.[ 3][ Level of evidence: 1iiA] Other agents with modest single-agent activity include vinca alkaloids, platinum compounds, and taxanes.[ 31, 32, 34]"